History
Neuronostics’ mission is to enhance the way neurological conditions are diagnosed, treated, and monitored. We use mathematical modelling to develop digital biomarkers that shorten the path to diagnosis and effective treatment
A short introduction to Neuronostics
In 2012, John Terry and Wessel Woldman began joint research into the mathematical analysis of EEG signals. Building on a patented invention of John’s from that year, they published the methodology underpinning BioEP, a digital biomarker for epilepsy, in a series of subsequent papers. In 2018 they launched Neuronostics from the University of Exeter to enhance neurological care with digital biomarkers built upon mathematical models and analysis.
BioEP analyses background EEG activity, not seizure activity, and provides objective diagnostic support when a routine EEG is inconclusive. It is a UKCA-marked medical device and has been used or studied across 30 NHS trusts and two health boards. In September 2024, Neuronostics won the Epilepsy Foundation of the USA Shark Tank competition in Atlanta, with a $125,000 prize to develop BioEP further and help shorten the time to diagnosis in the USA and globally.
Since 2018, Neuronostics has raised more than £5M across three investment rounds, alongside more than £5.5M in non-dilutive grants and contracts. We continue to research and develop new technology, with the goal of improving the lives of people with neurological conditions around the world.
Year founded
Spun out of the University of Exeter
Awards
for our work in medtech innovation both nationally and internationally
Our History
For over a decade, we have been developing the technology behind novel digital biomarkers of neurological conditions, however we didn’t even have a name back then. Since then, a lot has happened. Here is a history of our significant moments and achievements.
Partnership with EEG headset and software provider Stratus supporting joint contract discussions in the USA and Middle East
Neuronostics secures £570k NHS contract to develop BioEP for paediatrics
Multisite retrospective validation study of BioEP in paediatrics commenced – OASIS
Review of network-based biomarkers in EEG in childhood epilepsies published in Seizure: European Journal of Epilepsy
Partnership with EEG service distributor Nervus supporting joint NHS contract discussions
Multiple NHS service evaluations of BioEP for diagnosis underway
Neuronostics wins Epilepsy Foundation Shark Tank 2024
Partnership with EEG headset provider Neuroelectrics targeting pharma and medical device companies, with first commercial discussions underway
Multisite observational prospective study of BioEP for prognosis commenced – ECLIPSE
Multisite prospective study of BioEP for diagnosis commenced – CITADEL
Grants and contracts secured from Innovate UK (£350K - BioEP for Diagnosis, £500K - BioEP for Prognosis) and SBRI (£100K- Paediatric Epilepsy)
First prospective validation study of BioEP completed – PRISTINE
Multisite retrospective validation study of BioEP markers published in Epilepsia
Received ISO13485 certification for Neuronostics
NN raises over £2M in oversubscribed seed round
Awarded Epilepsy Positive Mark of Quality by Epilepsy Action
UKCA mark for Neuronostics platform
Patents assigned to Neuronostics
Strategic partnership with Epilepsy Action
Successful completetion of BioEP phase II trial
First UK revenue from our EEG remote reading service
We move into our offices at the Engine Shed Bristol
Neuronostics is accepted onto the SetSquared incubator program
BioEP class I CE marked
Complete oversubscribed pre seed investment round
Awarded £870K from NIHR AI in Health and Care Program
Awarded £50,000 from Innovate UK to develop Epilepsy App
BioEP prototype platform finalised
NN Secures funding from Innovate UK and University of Exeter
Successful BioEP phase 1 trial
Awarded £500K from the Innovate UK Health and Life Sciences fund
NN is incorporated
Founders John and Wes Embark on Innovate UK funded ICURe programme
Patent application filed for BioEP
We're award-winning
